Drug intelligence / Profile preview

S.Br@DBCO

Development stage: Preclinical
Lead developer: Children's Hospital of Fudan University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

**S.Br@DBCO** is an experimental orally administered live-biotherapeutic construct consisting of the probiotic yeast *Saccharomyces boulardii* surface-modified with dibenzocyclooctyne. It was developed as part of a bioorthogonal, inflammation-targeted strategy for inflammatory bowel disease: S.Br@DBCO is intended to bind azide-modified Prussian blue nanozyme at inflamed intestinal sites through copper-free azide-DBCO click chemistry. In a dextran sulfate sodium mouse colitis model, the paired PB@N3 plus S.Br@DBCO system increased intestinal probiotic retention, restored intestinal-barrier function, reduced intestinal inflammation, and improved colitis-associated outcomes. It is a preclinical research-stage construct and is not an approved medicine. ([academic.oup.com](https://academic.oup.com/ecco-jcc/article/19/Supplement_1/i2363/7971979))

Other names: DBCO-modified Saccharomyces boulardiiS.Br@DBCO

Beyond the preview

Go deeper on S.Br@DBCO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S.Br@DBCO.

Explore the full profile